NFCR joins the nation in mourning the passing of former President James (Jimmy) Carter
National Foundation for Cancer Research (NFCR) shared on LinkedIn:
“The National Foundation for Cancer Research joins the nation in mourning the passing of former President James (Jimmy) Carter.
President Carter’s courage in the face of his melanoma diagnosis and his treatment with immunotherapy remain a powerful testament to the progress made possible through cancer research.
In 2015, President Carter received immunotherapy using pembrolizumab, a treatment that harnesses the body’s immune system to fight cancer.
His recovery was a beacon of hope and demonstrated the transformative potential of immunotherapy, one of the most promising areas of modern cancer research.
As an organization dedicated to advancing innovative treatments like immunotherapy, the National Foundation for Cancer Research remains committed to ensuring that research breakthroughs continue to bring life-saving solutions to patients worldwide.
We honor President Carter’s legacy, including his support for national efforts to fight cancer, and extend our heartfelt condolences to his family during this time.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023